Pinebridge Investments L.P. Invests $3.68 Million in Hologic, Inc. (NASDAQ:HOLX)

Share on StockTwits

Pinebridge Investments L.P. bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 76,526 shares of the medical equipment provider’s stock, valued at approximately $3,675,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HOLX. FMR LLC increased its stake in shares of Hologic by 419.2% in the 1st quarter. FMR LLC now owns 13,264,384 shares of the medical equipment provider’s stock valued at $641,996,000 after purchasing an additional 10,709,693 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Hologic by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 3,805,329 shares of the medical equipment provider’s stock valued at $156,146,000 after purchasing an additional 190,788 shares during the last quarter. Northern Trust Corp increased its stake in shares of Hologic by 2.2% in the 1st quarter. Northern Trust Corp now owns 3,276,578 shares of the medical equipment provider’s stock valued at $158,587,000 after purchasing an additional 69,596 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Hologic by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,166,835 shares of the medical equipment provider’s stock valued at $89,051,000 after purchasing an additional 8,284 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Hologic by 5.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,043,496 shares of the medical equipment provider’s stock valued at $98,129,000 after purchasing an additional 114,554 shares during the last quarter. Institutional investors own 95.20% of the company’s stock.

In other news, Chairman Stephen P. Macmillan sold 194,396 shares of Hologic stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $48.77, for a total value of $9,480,692.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter J. Valenti III sold 7,766 shares of Hologic stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $49.14, for a total value of $381,621.24. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by insiders.

HOLX traded down $0.10 during midday trading on Friday, hitting $49.72. 1,000,689 shares of the company were exchanged, compared to its average volume of 1,375,661. The firm has a market capitalization of $13.32 billion, a P/E ratio of 22.30, a P/E/G ratio of 2.26 and a beta of 0.78. Hologic, Inc. has a 1-year low of $37.47 and a 1-year high of $52.19. The firm’s 50 day moving average price is $49.62 and its 200-day moving average price is $47.45. The company has a quick ratio of 1.11, a current ratio of 1.57 and a debt-to-equity ratio of 1.27.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.02. The firm had revenue of $852.40 million for the quarter, compared to the consensus estimate of $836.91 million. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The business’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.58 EPS. On average, sell-side analysts predict that Hologic, Inc. will post 2.44 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on HOLX. Canaccord Genuity reiterated a “hold” rating and issued a $52.00 price target on shares of Hologic in a research note on Thursday, August 1st. Needham & Company LLC reiterated a “buy” rating and issued a $57.00 price target (up previously from $52.00) on shares of Hologic in a research note on Thursday, August 1st. ValuEngine lowered Hologic from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. TheStreet upgraded Hologic from a “c+” rating to a “b” rating in a research note on Wednesday, July 31st. Finally, BTIG Research reiterated a “buy” rating and issued a $52.00 price target on shares of Hologic in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $50.12.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Gap Down Stocks

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.